IPF COMFORT Study for Chronic Cough Request More Information Trial Objective The IPF COMFORT Study is a clinical research study in patients with coughing attributed to Idiopathic Pulmonary Fibrosis. The investigational drug the study is testing is a once a day tablet called orvepitant. The cough in IPF may be caused by the airways becoming oversensitive, and it is hoped that orvepitant will reduce this over-sensitivity. The purpose of the IPF COMFORT Study is to see if orvepitant reduces the severity and burden of coughing in people with IPF. The study will also test the safety of orvepitant, how the drug is absorbed and used within the body. Orvepitant is an investigational medicine. This means that it is not approved for sale, but it is but it is approved for use in clinical studies like this one. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate People ages 40 and older who have been diagnosed with Idiopathic Pulmonary Fibrosis and have had a troublesome cough lasting for at least 8 weeks that has not responded to other treatments Age: 40+ Gender: Any Gender Estimated Time Commitment Six study appointments over 17 weeks, with clinic visits every three to four weeks × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Kaitlin Fier 303.270.2852 Request More Information Trial Location National Jewish Main Campus, Denver, CO Additional Resources IPF COMFORT Study for Chronic Cough Trial Sponsors NeRRe Therapeutics Ltd Principal Investigators Jeff Swigris, DO, MS + × Jeff Swigris, DO, MS Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective The IPF COMFORT Study is a clinical research study in patients with coughing attributed to Idiopathic Pulmonary Fibrosis. The investigational drug the study is testing is a once a day tablet called orvepitant. The cough in IPF may be caused by the airways becoming oversensitive, and it is hoped that orvepitant will reduce this over-sensitivity. The purpose of the IPF COMFORT Study is to see if orvepitant reduces the severity and burden of coughing in people with IPF. The study will also test the safety of orvepitant, how the drug is absorbed and used within the body. Orvepitant is an investigational medicine. This means that it is not approved for sale, but it is but it is approved for use in clinical studies like this one.